Trial
NCT01222143
Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University Health Network, Toronto
Collaborators
Novartis Pharmaceuticals
Condition
Acute Myeloid Leukemia
Intervention
NOVE-HiDAC
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-06-22